Biotie appoints Panu Miettinen CFO
This article was originally published in Scrip
Executive Summary
Biotie Therapies, a drug development company focused on neurodegenerative and psychiatric disorders, and inflammatory and fibrotic liver disease, has appointed Panu Miettinen chief financial officer, effective 15 March. Mr Miettinen will be based in Finland reporting to Timo Veromaa, president and CEO. He is replacing Zack McNealy, who has been serving as interim CFO and will resume his prior duties as vice-president of finance and administration at the group's US subsidiary. Mr Miettinen was previously CFO of Elektrobit Corporation.